SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022
Frontiers in Public Health · 2023
DOI: 10.3389/fpubh.2023.1292932 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2023. Verfasst von Angela Koech und 14 weiteren Autor:innen. Beteiligte Einrichtung: Centre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya. Hauptthemen laut MEDLINE: Pregnant People, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, FIC NIH HHS.
Abstract (Originalsprache)
Background
Seroprevalence studies are an alternative approach to estimating the extent of transmission of SARS-CoV-2 and the evolution of the pandemic in different geographical settings. We aimed to determine the SARS-CoV-2 seroprevalence from March 2020 to March 2022 in a rural and urban setting in Kilifi County, Kenya.
Methods
We obtained representative random samples of stored serum from a pregnancy cohort study for the period March 2020 to March 2022 and tested for antibodies against the spike protein using a qualitative SARS-CoV-2 ELISA kit (Wantai, total antibodies). All positive samples were retested for anti-SARS-CoV-2 anti-nucleocapsid antibodies (Euroimmun, ELISA kits, NCP, qualitative, IgG) and anti-spike protein antibodies (Euroimmun, ELISA kits, QuantiVac; quantitative, IgG).
Results
A total of 2,495 (of 4,703 available) samples were tested. There was an overall trend of increasing seropositivity from a low of 0% [95% CI 0–0.06] in March 2020 to a high of 89.4% [95% CI 83.36–93.82] in Feb 2022. Of the Wantai test-positive samples, 59.7% (95% CI 57.06–62.34) tested positive by the Euroimmun anti-SARS-CoV-2 NCP test and 75.9% (95% CI 73.55–78.17) tested positive by the Euroimmun anti-SARS-CoV-2 QuantiVac test. No differences were observed between the urban and rural hospital but villages adjacent to the major highway traversing the study area had a higher seroprevalence.
Conclusion
Anti-SARS-CoV-2 seroprevalence rose rapidly, with most of the population exposed to SARS-CoV-2 within 23 months of the first cases. The high cumulative seroprevalence suggests greater population exposure to SARS-CoV-2 than that reported from surveillance data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre of Excellence in Women and Child Health, Aga Khan University, Nairobi, Kenya.
- Department of Obstetrics and Gynaecology, Aga Khan University, Nairobi, Kenya.
- Department of Pathology, Aga Khan University, Nairobi, Kenya.
- Kilifi County Department of Health and Sanitation Services, Kilifi, Kenya.
- Department of Women and Children's Health, Kings College London, London, United Kingdom.
- Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium.
Förderung
- Medical Research Council
- FIC NIH HHS
Zitieren
APA
Koech, A., Omuse, G., Mugo, A. G., Mwaniki, I. G., Mutunga, J. M., Mukhanya, M. W., Wanje, O., Mwashigadi, G. M., Katana, G. G., Craik, R., von Dadelszen, P., Le Doare, K., Temmerman, M., periCOVID-Africa, & PRECISE Network (2023). SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2023.1292932
Vancouver
Koech A, Omuse G, Mugo AG, Mwaniki IG, Mutunga JM, Mukhanya MW, et al. SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022. Frontiers in Public Health. 2023. doi:10.3389/fpubh.2023.1292932
BibTeX
@article{Koech2023,
author = {Koech, Angela and Omuse, Geoffrey and Mugo, Alex G and Mwaniki, Isaac G and Mutunga, Joseph M and Mukhanya, Moses W and Wanje, Onesmus and Mwashigadi, Grace M and Katana, Geoffrey G and Craik, Rachel and von Dadelszen, Peter and Le Doare, Kirsty and Temmerman, Marleen and periCOVID-Africa, periCOVID-Africa and PRECISE Network, PRECISE Network},
title = {SARS-CoV-2 seroprevalence in pregnant women in Kilifi, Kenya from March 2020 to March 2022},
journal = {Frontiers in Public Health},
year = {2023},
doi = {10.3389/fpubh.2023.1292932}
}
EUVIMED